Immutep Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMMP Nasdaq 2836 www.immutep.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immutep Limited

Immutep Quarterly Activities Report Q4 FY26 - Jul 30th, 2026 6:00 am
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Jul 24th, 2026 6:00 am
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - Jul 21st, 2026 11:00 am
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor - Jul 14th, 2026 6:00 am
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - Jul 13th, 2026 11:00 am
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 - Jul 13th, 2026 6:00 am
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 - Jun 4th, 2026 6:00 am
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients - May 28th, 2026 6:00 am
Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans? - May 10th, 2026 4:03 pm
Immutep Quarterly Activities Report Q3 FY26 - Apr 30th, 2026 6:00 am
Immutep Receives Nasdaq Notice of Bid Price Deficiency - Apr 30th, 2026 6:00 am
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Apr 22nd, 2026 6:00 am
Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma - Apr 20th, 2026 8:47 pm
Sector Update: Health Care Stocks Decline Late Afternoon - Apr 15th, 2026 1:56 pm
Sector Update: Health Care Stocks Lower in Afternoon Trading - Apr 15th, 2026 11:55 am
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - Apr 15th, 2026 6:00 am
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases - Mar 19th, 2026 6:00 am
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls - Mar 14th, 2026 7:42 am
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination - Mar 13th, 2026 1:02 pm